380 related articles for article (PubMed ID: 12877088)
1. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
2. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Fujisawa T; Ikegami H; Inoue K; Kawabata Y; Ogihara T
Metabolism; 2005 Mar; 54(3):387-90. PubMed ID: 15736118
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
4. [Combination therapy with insulin and alpha-glucosidase inhibitor].
Watanabe K; Kawamori R
Nihon Rinsho; 2002 Sep; 60 Suppl 9():447-51. PubMed ID: 12387032
[No Abstract] [Full Text] [Related]
5. [alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
Odaka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():393-8. PubMed ID: 12387024
[No Abstract] [Full Text] [Related]
6. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
7. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
8. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
[TBL] [Abstract][Full Text] [Related]
9. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
[TBL] [Abstract][Full Text] [Related]
10. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
11. [Nateglinide and mitiglinide].
Odawara M
Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
[TBL] [Abstract][Full Text] [Related]
12. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
13. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.
Vichayanrat A; Ploybutr S; Tunlakit M; Watanakejorn P
Diabetes Res Clin Pract; 2002 Feb; 55(2):99-103. PubMed ID: 11796175
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.
Islas-Andrade S; Revilla-Monsalve MC; Martínez de Hurtado E; Chacín LF; Caminos QR; Yupanqui H; López G; de la Torre W;
Pharmacology; 2003 Jun; 68(2):89-95. PubMed ID: 12711836
[TBL] [Abstract][Full Text] [Related]
17. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
[TBL] [Abstract][Full Text] [Related]
18. Postprandial lipid profile in patients with type 2 diabetes.
Katsiki N; Kolovou G
Curr Med Res Opin; 2014 Jan; 30(1):121. PubMed ID: 24024786
[No Abstract] [Full Text] [Related]
19. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
20. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
